Randomized Trial of Marine n-3 Polyunsaturated Fatty Acids for the Prevention of Cerebral Small Vessel Disease and Inflammation in Aging (PUFA Trial): Rationale, Design and Baseline Results

Vascular risk factors for age-related cognitive decline are significant, and their management may ultimately prove the most successful strategy for reducing risk and sustaining cognitive health. This randomized, double-blinded, placebo-controlled trial with parallel group allocation to either marine n-3 polyunsaturated fatty acids (n-3 PUFA) or soybean oil placebo assesses the effects on the total volume of accumulation in cerebral white matter hyperintensities (WMH), a potentially modifiable neurovascular component of age-related cognitive decline. Total WMH accumulation over 3 years is the primary endpoint. The safety and efficacy of n-3 PUFA is evaluated in older adults with significant WMH and suboptimum plasma n-3 PUFA as inclusion criteria. One hundred and two non-demented older adults were enrolled with a mean age of 81.1 (±4.4) years, WMH of 19.4 (±16.1) cm3, and a plasma n-3 PUFA of 86.64 (±29.21) µg/mL. 61% were female, 28% were apolipoprotein E epsilon 4 carriers, and the mean mini-mental state exam (MMSE) was 27.9 (±1.7). This trial provides an initial evaluation of n-3 PUFA effects on WMH, a reproducible and valid risk biomarker for cognitive decline, as well as on inflammatory biomarkers thought to play a role in WMH accumulation. We present the baseline results and operational experience of enriching a study population on advanced age, blood n-3 PUFA, and magnetic resonance imaging (MRI) derived WMH with biomarker outcomes (WMH, inflammation markers) in a dementia prevention paradigm.

[1]  Prevention Study , 2020, Definitions.

[2]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[3]  J. Manson,et al.  Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer , 2019, The New England journal of medicine.

[4]  N. Bazan.  Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection. , 2018, Molecular aspects of medicine.

[5]  D. Norris,et al.  Memory decline in elderly with cerebral small vessel disease explained by temporal interactions between white matter hyperintensities and hippocampal atrophy , 2018, Hippocampus.

[6]  J. Wojcik,et al.  Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults , 2018, Alzheimer's & Dementia.

[7]  E. Mormino,et al.  APOE genotype and early β-amyloid accumulation in older adults without dementia , 2017, Neurology.

[8]  Erick J. Paul,et al.  Predictors of Memory in Healthy Aging: Polyunsaturated Fatty Acid Balance and Fornix White Matter Integrity , 2017, Aging and disease.

[9]  S. Lehéricy,et al.  Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial , 2017, The Lancet Neurology.

[10]  A. Green,et al.  Plasma eicosapentaenoic acid is negatively associated with all-cause mortality among men and women in a population-based prospective study. , 2016, Nutrition research.

[11]  Blair H. Smith,et al.  GWAS for executive function and processing speed suggests involvement of the CADM2 gene , 2016, Molecular Psychiatry.

[12]  David L. Lahna,et al.  Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures , 2015, NeuroImage: Clinical.

[13]  Lucia Kerti,et al.  Long-chain omega-3 fatty acids improve brain function and structure in older adults. , 2014, Cerebral cortex.

[14]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[15]  Hiroko H. Dodge,et al.  Plasma omega-3 PUFA and white matter mediated executive decline in older adults , 2013, Front. Aging Neurosci..

[16]  D. Mozaffarian,et al.  Circulating Omega‐3 Polyunsaturated Fatty Acids and Subclinical Brain Abnormalities on MRI in Older Adults: The Cardiovascular Health Study , 2013, Journal of the American Heart Association.

[17]  D. Salmon,et al.  The Multilingual Naming Test in Alzheimer's Disease: Clues to the Origin of Naming Impairments , 2013, Journal of the International Neuropsychological Society.

[18]  W. Harris,et al.  Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers , 2013, Nutritional neuroscience.

[19]  D. Holtzman,et al.  Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.

[20]  Cécile Proust-Lima,et al.  Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe , 2012, Neurology.

[21]  Steven Hou,et al.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. , 2012, Brain : a journal of neurology.

[22]  C. Annweiler,et al.  Nutrient Biomarker Patterns, Cognitive Function, and Mri Measures of Brain Aging , 2012, Neurology.

[23]  Jie Cao,et al.  Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. , 2012, Atherosclerosis.

[24]  C. DeCarli,et al.  Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging , 2012, Neurology.

[25]  C. Moy,et al.  Vascular risk factors and cognitive impairment in a stroke-free cohort , 2011, Neurology.

[26]  M. Weiner,et al.  Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample , 2011, Neurology.

[27]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[28]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[29]  J. Kramer,et al.  Mild cognitive impairment, dementia, and their subtypes in oldest old women. , 2011, Archives of neurology.

[30]  H. Dodge,et al.  Risk of Alzheimer's disease incidence attributable to vascular disease in the population , 2011, Alzheimer's & Dementia.

[31]  Barry Oken,et al.  Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment , 2011, Alzheimer disease and associated disorders.

[32]  N. Venketasubramanian,et al.  The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke , 2010, Journal of the Neurological Sciences.

[33]  K. Jellinger,et al.  Is there pure vascular dementia in old age? , 2010, Journal of the Neurological Sciences.

[34]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[35]  P. Calder,et al.  Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. , 2010, Atherosclerosis.

[36]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[37]  D. Ding,et al.  Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects , 2009, Clinical Neurology and Neurosurgery.

[38]  L. D. de Groot,et al.  Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. , 2009, The American journal of clinical nutrition.

[39]  J. Kaye,et al.  Cognitive impairment risk , 2009, Neurology.

[40]  H. Markus,et al.  The Genetics of Cervical Artery Dissection: A Systematic Review , 2009, Stroke.

[41]  Anders M. Dale,et al.  MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.

[42]  M. Weiner,et al.  Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease* , 2009, Brain : a journal of neurology.

[43]  B. Mazoyer,et al.  Longitudinal follow-up of individual white matter hyperintensities in a large cohort of elderly , 2009, Neuroradiology.

[44]  Lewis H Kuller,et al.  Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.

[45]  D. Mozaffarian,et al.  Fish consumption and risk of subclinical brain abnormalities on MRI in older adults , 2008, Neurology.

[46]  R Brookmeyer,et al.  Prevalence of dementia after age 90 , 2008, Neurology.

[47]  J. Kaye,et al.  Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline , 2008, Neurology.

[48]  J. Quinn,et al.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future. , 2008, Aging health.

[49]  P. Sachdev,et al.  Ocular dipping and ping-pong gaze in hypoxic encephalopathy , 2007, Neurology.

[50]  Thomas D. Parsons,et al.  Timed Gait Test: Normative Data for the Assessment of the AIDS Dementia Complex , 2006, Journal of clinical and experimental neuropsychology.

[51]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[52]  L. H. Kuller,et al.  Benefits of fatty fish on dementia risk are stronger for those without APOE ε4 , 2005, Neurology.

[53]  M. Woodward,et al.  Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy , 2005, Circulation.

[54]  A. Leaf,et al.  Omega-3 fatty acids and ventricular arrhythmias. , 2005, World review of nutrition and dietetics.

[55]  C. Enzinger,et al.  Markers of Endothelial and Hemostatic Activation and Progression of Cerebral White Matter Hyperintensities: Longitudinal Results of the Austrian Stroke Prevention Study , 2005, Stroke.

[56]  M. van Buchem,et al.  Effect of pravastatin on cerebral infarcts and white matter lesions , 2005, Neurology.

[57]  D. Harvey,et al.  Measures of brain morphology and infarction in the framingham heart study: establishing what is normal , 2005, Neurobiology of Aging.

[58]  D. Mozaffarian,et al.  Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. , 2005, Archives of internal medicine.

[59]  A. Witkowska,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. , 2004, European cytokine network.

[60]  P. Sham,et al.  Endothelial Nitric Oxide Gene Haplotypes and Risk of Cerebral Small-Vessel Disease , 2004, Stroke.

[61]  T. Tombaugh.  Trail Making Test A and B: normative data stratified by age and education. , 2004, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[62]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[63]  L. Kappelle,et al.  Endothelial Cell Activation Is Associated with Cerebral White Matter Lesions in Patients with Cerebrovascular Disease , 2002, Annals of the New York Academy of Sciences.

[64]  T. O. Meyer,et al.  Observation of the decay Omega(0)(c)-->Omega(-)e(+)nu(e). , 2002, Physical review letters.

[65]  J. Dietrich.  The adhesion molecule ICAM-1 and its regulation in relation with the blood–brain barrier , 2002, Journal of Neuroimmunology.

[66]  C. Jun,et al.  Ultrastructure and Function of Dimeric, Soluble Intercellular Adhesion Molecule-1 (ICAM-1)* , 2001, The Journal of Biological Chemistry.

[67]  C. Jun,et al.  Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. A. Peterson,et al.  A key role for ICAM-1 in generating effector cells mediating inflammatory responses , 2001, Nature Immunology.

[69]  J. Manson,et al.  Intake of fish and omega-3 fatty acids and risk of stroke in women. , 2001, JAMA.

[70]  R. Martins,et al.  Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.

[71]  H. Schouten,et al.  Adaptive biased urn randomization in small strata when blinding is impossible. , 1995, Biometrics.

[72]  N. Squires,et al.  Construct validity in the Trail Making Test: what makes Part B harder? , 1995, Journal of clinical and experimental neuropsychology.

[73]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[74]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[75]  T. Salthouse.  What do adult age differences in the Digit Symbol Substitution Test reflect? , 1992, Journal of gerontology.

[76]  P. Paré,et al.  Evidence for inflammation in asthma. , 1991, The American review of respiratory disease.

[77]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[78]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[79]  P. Zandi,et al.  Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. , 2005, Neurology.

[80]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[81]  P A Parmelee,et al.  Geriatric Depression Scale , 2002 .